Expect immediate selling pressure given the highly dilutive structure relative to market cap. The three-tranche structure with escalating dilution at $3.74/share (near current price) suggests material share overhang. Monitor the annual meeting for shareholder vote on warrant shares; failure could trigger adverse terms. The lock-up on the White Lion facility is a positive but minor offset.
Price Chart
Executive Summary
Akari Therapeutics entered into a securities purchase agreement to raise approximately $5.5 million in gross proceeds through a three-tranche private placement priced at $3.74 per ADS. The offering includes pre-funded warrants exercisable immediately and three series of warrants (Series H, I, J) with a $3.74 strike price and 5-year term, all subject to shareholder approval. The company also terminated its existing equity line with White Lion Capital, removing the overhang of that facility.
Key Financial Metrics
Key Facts
- Gross proceeds of ~$5.5 million from a three-tranche private placement priced at $3.74 per ADS
- Initial closing of $1,833,333 expected May 27, 2026, with second and third closings on June 15 and July 15
- Each tranche includes Series H, I, and J warrants exercisable at $3.74 for five years, in an amount equal to 100% of the ADSs purchased per tranche
- Company must seek shareholder approval at its 2026 annual meeting to issue the warrant shares
- The August 2025 purchase agreement with White Lion Capital remains in effect but is subject to a lock-up restricting further draws for 45 days
- Proceeds to be used for working capital purposes
- Market cap is approximately $6M, making this offering size very large relative to existing equity
- 80% of analysts rate the stock a Buy or Strong Buy, suggesting this dilutive financing may signal more acute capital needs than previously understood
Financial Impact
~$5.5M gross proceeds with severe dilution relative to a ~$6M market cap; potential for further dilution from warrant exercises
Risk Factors
- Massive dilution at $6M market cap — total potential shares including warrants could far exceed current float
- Shareholder approval may be difficult to obtain given the magnitude of dilution
- Downward price pressure as investors price in dilutive overhang
- Second and third closings are not guaranteed — if conditions fail, the company may still need additional capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025037 |
| Exhibit: ex4-1.htm | 0001493152-26-025037 |
| Exhibit: ex4-3.htm | 0001493152-26-025037 |
| Exhibit: ex4-4.htm | 0001493152-26-025037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $8.58 (−1.61%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $8.58 (−1.61%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $8.58 (+13.79%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $8.58 (+36.07%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $8.58 (−39.62%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $8.58 (+17.58%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.58 (−11.46%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.58 (−11.46%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $8.58 (−61.09%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $8.58 (+51.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers